Defense Stock Domin...
Health Care: Drugs
A.P. Pharma Inc. (APPA: OTC)
$0.42 -0.02 | -3.41%
05/23/13 - 03:59 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 0.00 | 646.00K | 1.30M | 1.26M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | -356.00K |
| Gross Operating Profit | 0.00 | 646.00K | 1.30M | 1.62M |
| Selling, General, and Administrative Expenses | 8.79M | 3.50M | 3.97M | 3.71M |
| Research & Development | 15.04M | 8.21M | 7.26M | 7.80M |
| Operating Income before D & A (EBITDA) | -23.83M | -11.06M | -9.93M | -9.89M |
| Depreciation & Amortization | 586.00K | 282.00K | 227.00K | 356.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 29.00K |
| Other Income - Net | 0.00 | 0.00 | 2.74M | -127.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -24.42M | -11.34M | -7.42M | -10.34M |
| Interest Expense | 599.00K | 373.00K | 2.00K | 0.00 |
| Pre-Tax Income | -25.02M | -11.72M | -7.42M | -10.34M |
| Income Taxes | 0.00 | 0.00 | 0.00 | -122.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -24.43M | -11.44M | -7.20M | -10.22M |
| Net Income From Discontinued Operations | 1.08M | -379.00K | -150.00K | 0.00 |
| Net Income From Total Operations | -23.35M | -11.81M | -7.35M | -10.22M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 190.00K |
| Total Net Income | -23.35M | -11.81M | -7.35M | -10.03M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-24.43M | -11.44M | -7.20M | -10.22M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -24.43M | -11.44M | -7.20M | -10.22M |
| Basic EPS from Continuing Ops. | -0.10 | -0.10 | -0.18 | -0.31 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | -0.01 | 0.00 |
| Basic EPS from Total Operations | -0.10 | -0.10 | -0.19 | -0.31 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.10 | -0.10 | -0.19 | -0.31 |
| Basic Normalized Net Income/Share | -0.10 | -0.10 | -0.18 | -0.31 |
| EPS fr Continuing Ops. | -0.10 | -0.10 | -0.18 | -0.31 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS fr Total Ops. | -0.10 | -0.10 | -0.19 | -0.31 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.10 | -0.10 | -0.19 | -0.31 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.10 | -0.10 | -0.18 | -0.31 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with APPA
- Portfolio NameUser Type
- UserMy Folio
- Userwatchlist1
- UserMARK 1 C
- ContributorBarron's Insider Purchases ...
- UserSUPRATRADE-2709091838
- UserLatest Activist Filings 2-2...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- UserBarron's Insider Purchases ...
Latest APPA Headlines from TheStreet
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- The Next Big Thing In Biotech: Decision Week
03.21.13 | 09:03 am - Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
- Play TheStreet's FDA Drug Approval Contest 03.05.13 | 12:03 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- A.P. Pharma Run-Up Trade Into FDA Approval Decision 01.22.13 | 08:01 am
- AP Pharma, Delcath Systems: FDA 'Acceptance' Run-Up Trades 10.09.12 | 07:10 am
- Ambac Financial, QAD: Early Volume Plays 05.18.10 | 08:05 am
- A.P. Pharma, Netlist: Early Volume Plays 03.19.10 | 10:03 am
- Biotech Stock Mailbag: Sequenom 03.12.10 | 07:03 am
Press Releases for APPA
- A.P. Pharma Receives FDA Complete Response Letter For APF530 - Business Wire 03.28.13 | 07:03 am
- A.P. Pharma Announces Fourth Quarter And Full Year 2012 Financial Results And Highlights Recent Corporate Progress - Business Wire 03.01.13 | 08:03 am
- A.P. Pharma Appoints Jesse Hollingsworth As Vice President Of Sales - Business Wire 02.28.13 | 08:02 am
- A.P. Pharma Names Mark S. Gelder, M.D. As Senior Vice President And Chief Medical Officer - Business Wire 12.13.12 | 08:12 am
- A.P. Pharma Announces Third Quarter 2012 Financial Results And Highlights Recent Corporate Progress - Business Wire 11.05.12 | 08:11 am
- A.P. Pharma Appoints Robert Rosen As Senior Vice President And Chief Commercial Officer - Business Wire 10.18.12 | 08:10 am
- A.P. Pharma Announces PDUFA Action Date For APF530 New Drug Application Resubmission - Business Wire 10.16.12 | 08:10 am
- A.P. Pharma Resubmits New Drug Application For APF530, A Product Candidate For The Prevention Of Chemotherapy-Induced Nausea And Vomiting - Business Wire 09.28.12 | 08:09 am
- A.P. Pharma Appoints Thomas Pitler, Ph.D. As Vice President Of Business Development - Business Wire 09.10.12 | 08:09 am
- A.P. Pharma Announces Second Quarter 2012 Financial Results And Highlights Recent Corporate Progress - Business Wire 08.02.12 | 08:08 am
Partner Headlines for APPA
- REVEALED: New Analyst Stock Coverage to Assess Today - Wall St. Cheat Sheet 06.13.12 | 04:06 am
- Mannkind Slashes Staff: Biotech's Latest Tribulations - Seeking Alpha 02.13.11 | 08:02 am
- UPDATE 3-FDA denies approval of AP Pharma nausea drug; shrs sink - Reuters 03.19.10 | 12:03 pm
